Post hoc analysis of relationship between baseline white blood cell count and renal and hepatic function and response in a randomized phase III trial of decitabine in patients age 65 or older with acute myeloid leukemia.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6632-6632
Author(s):  
Jacques Delaunay ◽  
Grzegorz Mazur ◽  
Mark D Minden ◽  
Agnieszka Wierzbowska ◽  
Mark M. Jones ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Cell ◽  
White Blood Cell ◽  
Myeloid Leukemia ◽  
Hepatic Function ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Post Hoc Analysis ◽  
Post Hoc ◽  
Acute Myeloid

6632 Background: A phase III trial (NCT00260832) in patients (N=485) ≥65y with newly diagnosed acute myeloid leukemia (AML) was conducted (Kantarjian, JCO; in press). Every 4 wk, patients received decitabine (DAC) 20 mg/m2 (1-h intravenous infusion, 5 successive days) or treatment choice (TC) with either supportive care or cytarabine (20 mg/m2 subcutaneous injection daily, 10 successive days). This post hoc analysis examined whether baseline (BL) renal and hepatic function and white blood cell (WBC) counts were associated with response to DAC or TC. Methods: For patients with available data, BL WBC count and markers of renal function (blood urea nitrogen [BUN], creatinine) and liver function (ALT, AST, albumin) were tabulated for patients with/without a response to DAC or TC. Response was defined as morphologic complete remission (CR), CR with incomplete blood count recovery (CRi), or partial remission (PR). Results: Nonresponders had a higher mean BL creatinine vs responders (86.78 vs 80.23 mmol/L, respectively; P=.005); with no differences in BL BUN levels. There were no other between-group differences. Conclusions: This analysis suggests that there is no relationship between BL WBC or hepatic function and response to treatment with DAC or TC. Although there was no difference in BL BUN, higher mean creatinine levels in nonresponders may suggest a prognostic relationship but further studies are needed to clarify. [Table: see text]

scholarly journals Post hoc analysis of relationship between baseline white blood cell count and survival outcome in a randomized phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 6559-6559
Author(s):  
Chris Arthur ◽  
Jaroslav Cermak ◽  
Jacques Delaunay ◽  
Jiri Mayer ◽  
Grzegorz Mazur ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Myeloid Leukemia ◽  
Survival Outcome ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Phase Iii Trial ◽  
Post Hoc Analysis ◽  
Wbc Count ◽  
Post Hoc ◽  
Acute Myeloid

6559 Background: In a large phase III trial (N=485), patients (pts) ≥65y with newly diagnosed acute myeloid leukemia (AML) received 1-h IV infusion of decitabine (DAC) 20 mg/m2 for 5 consecutive days every 4 wk or treatment choice (TC) with supportive care or cytarabine 20 mg/m2 subcutaneous injection for 10 consecutive days every 4 wk (NCT00260832; Kantarjian et al. JCO, in press). Enrolled pts had white blood cell (WBC) count <40 x109/L; baseline WBC counts were relatively low (median [range] DAC: 3.1 x109/L [0.3-127.0]; TC: 3.7 x109/L [0.5-80.9]). This post hoc analysis assessed baseline WBC count and survival outcome. Methods: Overall survival (OS) and progression-free survival (PFS) were summarized by baseline WBC subgroups (<1, 1-5, >5 x109/L). Results: Mature survival data (2010) were based on intent-to-treat (ITT) population (446 deaths: TC, n=227; DAC, n=219). OS was 5.0 mo for TC vs 7.7 mo for DAC (nominal P=.037). For each WBC subgroup, differences in OS for TC vs DAC were not significant (NS), but hazard ratios (HR) favored DAC for all subgroups (Table). There was a significant difference in PFS in favor of DAC for patients with baseline WBC 1–5 x109/L (P=.005; HR=0.67) and >5 x109/L (P=.027; HR=0.71). Conclusions: These data are consistent with overall results, with a trend toward improved outcome with DAC regardless of baseline WBC count in older pts with newly diagnosed AML. Further analyses are warranted. [Table: see text]

scholarly journals Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia

2014 ◽  
Vol 3 (1) ◽  
pp. 17-20 ◽  
Author(s):  
Jacques Delaunay ◽  
Grzegorz Mazur ◽  
Mark Minden ◽  
Agnieszka Wierzbowska ◽  
Mark M. Jones ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Hepatic Function ◽  
Blood Cell Count ◽  
Acute Myeloid

scholarly journals Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD

Haematologica ◽  
2011 ◽  
Vol 96 (9) ◽  
pp. 1310-1317 ◽  
Author(s):  
H. J. M. de Jonge ◽  
P. J. M. Valk ◽  
E. S. J. M. de Bont ◽  
J. J. Schuringa ◽  
G. Ossenkoppele ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Blood Cell ◽  
Cell Count ◽  
White Blood Cell Count ◽  
White Blood Cell ◽  
Myeloid Leukemia ◽  
Prognostic Impact ◽  
Intermediate Risk ◽  
Blood Cell Count ◽  
Acute Myeloid

scholarly journals Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia

2012 ◽  
Vol 30 (21) ◽  
pp. 2670-2677 ◽  
Author(s):  
Hagop M. Kantarjian ◽  
Xavier G. Thomas ◽  
Anna Dmoszynska ◽  
Agnieszka Wierzbowska ◽  
Grzegorz Mazur ◽  
...  
Keyword(s):  
Acute Myeloid Leukemia ◽  
Older Patients ◽  
Myeloid Leukemia ◽  
Phase Iii ◽  
Newly Diagnosed ◽  
Primary Analysis ◽  
Open Label ◽  
Phase Iii Trial ◽  
Open Label Phase ◽  
Acute Myeloid

Purpose This multicenter, randomized, open-label, phase III trial compared the efficacy and safety of decitabine with treatment choice (TC) in older patients with newly diagnosed acute myeloid leukemia (AML) and poor- or intermediate-risk cytogenetics. Patients and Methods Patients (N = 485) age ≥ 65 years were randomly assigned 1:1 to receive decitabine 20 mg/m2 per day as a 1-hour intravenous infusion for five consecutive days every 4 weeks or TC (supportive care or cytarabine 20 mg/m2 per day as a subcutaneous injection for 10 consecutive days every 4 weeks). The primary end point was overall survival (OS); the secondary end point was the complete remission (CR) rate plus the CR rate without platelet recovery (CRp). Adverse events (AEs) were recorded. Results The primary analysis with 396 deaths (81.6%) showed a nonsignificant increase in median OS with decitabine (7.7 months; 95% CI, 6.2 to 9.2) versus TC (5.0 months; 95% CI, 4.3 to 6.3; P = .108; hazard ratio [HR], 0.85; 95% CI, 0.69 to 1.04). An unplanned analysis with 446 deaths (92%) indicated the same median OS (HR, 0.82; 95% CI, 0.68 to 0.99; nominal P = .037). The CR rate plus CRp was 17.8% with decitabine versus 7.8% with TC (odds ratio, 2.5; 95% CI, 1.4 to 4.8; P = .001). AEs were similar for decitabine and cytarabine, although patients received a median of four cycles of decitabine versus two cycles of TC. The most common drug-related AEs with decitabine were thrombocytopenia (27%) and neutropenia (24%). Conclusion In older patients with AML, decitabine improved response rates compared with standard therapies without major differences in safety. An unplanned survival analysis showed a benefit for decitabine, which was not observed at the time of the primary analysis.

Sign in / Sign up

Export Citation Format

Share Document